drugset / Trial / NCT00232531

Oxford Niaspan Study: Effects of Niaspan on Atherosclerosis and Endothelial Function

NCT00232531

RandomizedParallel-groupDouble-blindPrevention

Summary

AIM 1 will test the hypothesis that elevation of high-density lipoprotein (HDL) through treatment with Niaspan will accelerate the regression of atherosclerotic plaque in patients with established atherosclerosis. The investigators will therefore study patients with atherosclerosis in the aorta and carotid artery. Plaque quantification will be with magnetic resonance imaging (MRI). AIM 2 will assess the ability of Niaspan to improve endothelial function in patients with coronary artery disease and type II diabetes mellitus, who typically have low high-density lipoprotein cholesterol (HDL-C), and high risk of cardiovascular events.

Timeline

Start
2004-09
Primary completion
Completion
2009-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Niacin Small molecule 2000 mg

Indications